Federal Register / Vol. 71, No. 230 / Thursday, November 30, 2006 / Notices 69211 

*** These percentages may change for some states pending comments received on implementation of Section 6053 (b) of the Deficit Reduction Act. 

[FR Doc. E6–20264 Filed 11–29–06; 8:45 am] 

BILLING CODE 4150–24–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20 1980, as amended 

most recently at 17 FR 50065, dated 

August 24, 2006) is amended to reflect 

the title change for the Division of 

Hereditary Blood Disorders, National 

Center on Birth Defects and 

Developmental Disabilities, 

Coordinating Center for Health 

Promotion, Centers for Disease Control 

and Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: 

Delete in its entirety the title for the 

Division of Hereditary Blood Disorders 

(CUBD), and insert the Division of Blood 

Disorders (CUBD). 

Dated: November 15, 2006. 

William H. Gimson, 

Chief Operating Officer, Centers for Disease 

Control and Prevention (CDC). 

[FR Doc. 06–9472 Filed 11–29–06; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Blood Products Advisory Committee; 

Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Blood Products 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on December 14, 2006, from 8 a.m. 

to 6 p.m. 

Location: Crown Plaza Silver Spring, 

8777 Georgia Ave, Silver Spring, MD. 

The hotel telephone number is 301–

589–0800. 

Contact Person: Donald W. Jehn, or 

Pearline K. Muckelvene, Center for 

Biologics Evaluation and Research 

(HFM–71), Food and Drug 

Administration, 1401 Rockville Pike, 

Rockville, MD 20852, 301–827–0314, or 

FDA Advisory Committee Information 

Line, 1–800–741–8138 (301–443–0572 

in the Washington, DC area), code 

3014519516. Please call the Information 

Line for up-to-date information on this 

meeting. 

Agenda: On December 14, 2006, the 

committee will hear an update summary 

of the October 11, 2006, Public Hearing 

on Emergency Research. The committee 

will then discuss pre-clinical and 

clinical studies of the hemoglobin-based 

oxygen carrier, bovine polymerized 

hemoglobin (HBOC–201). In addition, 

the committee will discuss an 

emergency research study of HBOC–

201, proposed by the Naval Medical 

Research Center. FDA intends to make 

background material available to the 

public no later than one business day 

before the meeting. If FDA is unable to 

post the background material on its Web 

site prior to the meeting, the background 

material will be made publicly available 

at the location of the advisory 

committee meeting, and the background 

material will be posted on FDA’s Web 

site after the meeting. Background 

material is available at http:// 

www.fda.gov/ohrms/dockets/ac/ 

acmenu.htm, click on the year 2006 and 

scroll down to the appropriate advisory 

committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before December 11, 2006. 

Oral presentations from the public will 

be scheduled between approximately 

1:15 p.m. and 2:15 p.m. Those desiring 

to make formal oral presentations 

should notify the contact person and 

submit a brief statement of the general 

nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and 

an indication of the approximate time 

requested to make their presentation on 

or before December 6, 2006. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public session, FDA 

may conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by December 7, 2006. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Donald W. 

Jehn or Pearline K. Muckelvene at least 

7 days in advance of the meeting. 

FDA regrets that it was unable to 

publish this notice 15 days prior to the 

December 14, 2006, Blood Products 

Advisory Committee meeting. Because 

the agency believes there is some 

urgency to bring this issue to public 

discussion and qualified members of the 

Blood Products Advisory Committee 

were available at this time, the 

Commissioner of Food and Drugs 

concluded that it was in the public 

interest to hold this meeting even if 

there was not sufficient time for the 

customary 15-day public notice. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: November 22, 2006. 

Randall W. Lutter, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E6–20265 Filed 11–29–06; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 


pwalker on PRODPC60 with NOTICES
69212 Federal Register / Vol. 71, No. 230 / Thursday, November 30, 2006 / Notices 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Development and Discovery. 

Date: February 7–9, 2007. 

Time: 5 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Peter J. Wirth, PhD, 

Scientific Review Administrator, Research 

Programs Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Boulevard, Room 

8131, Bethesda, MD 20892–8328. 301–496–

7565. pw2q@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SPORE II. 

Date: February 13–15, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Caron Lyman, Scientific 

Review Administrator, Division of 

Extramural Activities, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Blvd, Room 8119, Bethesda, MD 

20892–8328. 301–451–4761. 

lymanc@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: November 20, 2006. 

David Clary, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9469 Filed 11–29–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; GENSAT Review. 

Date: November 29, 2006. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Phillip F. Wiethorn, 

Scientific Review Administrator, DHHS/NIH/ 

NINDS/DER/SRB, 6001 Executive Boulevard, 

MSC 9529, Neuroscience Center, Room 3203, 

Bethesda, MD 20892–9529. (301) 496–5388. 

wiethorp@ninds.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: November 20, 2006. 

David Clary, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9466 Filed 11–29–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Emphasis Panel; 

Minority Biomedical Research Support 

SCORE and RISE. 

Date: December 1, 2006. 

Time: 9:30 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Room 

3AN–12, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Helen R. Sunshine, PhD, 

Chief, Office of Scientific Review, National 

Institute of General Medical Sciences, 

National Institutes of Health, Natcher 

Building, Room 3AN12F, Bethesda, MD 

20892. 301–594–2881. 

sunshinh@nigms.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS) 

Dated: November 20, 2006. 

David Clary, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9467 Filed 11–29–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Child Health and 

Human Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 


pwalker on PRODPC60 with NOTICES